IL-29, human recombinant | 4981

IL-29 is distantly related to type I interferons and the IL-10 family. Expression of IL-29 is induced by viral infection which interacts with a heterodimeric class II cytokine receptor that consists of interleukin 10 receptor (IL10RB) and interleukin 28 receptor . IL-29 exhibits common features with type I IFNs such as antiviral activity, antiproliferative activity and in vivo antitumour activity. IL-29 acts similarly to IFNs, but is less effective generally and has activity in a more limited range of cell lines. IL-29 produced in response to viral infection, activates both monocytes and macrophages producing a restricted panel of cytokines and therefore is an important factor in activating innate immune responses at the site of viral infection. IFN-Lambda 1 antiviral and antiproliferative activity requires Interferon-Lambda 2 receptor tyrosine residues. Recombinant human IL-29 produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 181 amino acids and having a molecular mass of 20 kDa.

4981 | IL-29 human recombinant DataSheet

Biomolecule/Target: N/A

Synonyms: Interleukin-29, IL-29, IFN-Lambda 1, Interferon-Lambda 1, Cytokine ZCYTO21, IL29, IFNL1, ZCYTO21,

Alternates names:

Taglines: A cytokine mediating adaptive immune response

NCBI Gene ID #: N/A

NCBI Gene Symbol: N/A

Gene Source: N/A

Accession #: N/A

Recombinant: Yes

Source: N/A

Purity by SDS-PAGEs: 95%

Assay: Western Blot

Purity: 90%

Assay #2: HPLC

Endotoxin Level: <0.1 ng/g

Activity (Specifications/test method): N/A

Biological activity: N/A

Results: N/A

Binding Capacity: N/A

Unit Definition: N/A

Molecular Weight: 17.139 kDa (Band migrates faster on Gels)

Concentration: N/A

Appearance: Lyophilized protein

Physical form description: Sterile filtered and lyophilized with no additives

Reconstitution Instructions: N/A

Amino acid sequence: N/A